To further demonstrate the applicability of our optimized ML model toward efficient antisense PNA sequence design, we predicted all possible 18‐mer antisense PNA candidates targeting human dystrophin gene exon 44, which contributes to ≈8% of Duchenne muscular dystrophy (DMD) patients but currently lacks treatments.[19] Three antisense PNA sequences were selected to represent easy, medium difficulty, and difficult sequences for synthesis, and the purified product yields validated the model predictions. This evidence concerns the gene DMD and Duchenne muscular dystrophy.